• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Projects
  • Research Data
  • Organizations
  • Researchers
  • More
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Characterization of Neisseria gonorrhoeae isolates detected in Switzerland (1998–2012): emergence of multidrug-resistant clones less susceptible to cephalosporins
 

Characterization of Neisseria gonorrhoeae isolates detected in Switzerland (1998–2012): emergence of multidrug-resistant clones less susceptible to cephalosporins

Options
  • Details
  • Files
BORIS DOI
10.7892/boris.44899
Publisher DOI
10.1186/1471-2334-14-106
PubMed ID
24568221
Description
Background: The spread of Neisseria gonorrhoeae (Ng) isolates resistant to the clinically implemented antibiotics is challenging the efficacy of treatments. Unfortunately, phenotypic and molecular data regarding Ng detected in
Switzerland are scarce.
Methods: We compared the characteristics of Ng detected during 1998–2001 (n = 26) to those detected during 2009–2012 (n = 34). MICs were obtained with the Etest and interpreted as non-susceptible (non-S) according to
EUCAST criteria. Sequence type (ST) was achieved implementing the NG-MAST. BlaTEM, ponA, penA, mtrR, penB, tet (M), gyrA, parC, mefA, ermA/B/C/F, rplD, rplV, and 23S rRNA genes were analyzed.
Results: The following susceptibility results were obtained (period: % of non-S, MIC90 in mg/L): penicillin (1998–2001:
42.3%, 3; 2009–2012: 85.3%, 16), cefixime (1998–2001: 0%, ≤0.016; 2009–2012: 8.8%, 0.125), ceftriaxone (1998–2001: 0%,
0.004; 2009–2012: 0%, 0.047), ciprofloxacin (1998–2001: 7.7%, 0.006; 2009–2012: 73.5%, ≥32), azithromycin (1998–2001:
11.5%, 0.25; 2009–2012: 23.6%, 0.38), tetracycline (1998–2001: 65.4%, 12; 2009–2012: 88.2%, 24), spectinomycin (1998–2001: 0%, 12; 2009–2012: 0%, 8). The prevalence of multidrug-resistant (MDR) isolates increased from 7.7% in 1998–2001 to 70.6% in 2009–2012. International STs and genogroups (G) emerged during 2009–2012 (G1407, 29.4%; G2992, 11.7%; G225, 8.8%). These isolates possessed distinctive mechanisms of resistance (e.g., G1407: PBP1 with L421, PBP2 pattern XXXIV, GyrA with S91F and D95G, ParC with S87R, PorB with G120K and A121N, mtrR promoter with A deletion).
Conclusions: The prevalence of penicillin- ciprofloxacin- and tetracycline-resistant Ng has reached dramatic levels, whereas cefixime and ceftriaxone show MICs that tend to increase during time. International MDR clones less susceptible to cephalosporins are rapidly emerging indicating that the era of untreatable gonococcal infections is close.
Date of Publication
2014
Publication Type
Article
Subject(s)
500 - Science::570 - Life sciences; biology
600 - Technology::610 - Medicine & health
Keyword(s)
Gonococcus
•
ST1407
•
MIC
•
Ceftriaxone
•
Cefixime
•
MDR
•
NG-MAST
•
PBP1
•
PBP2
•
Mosaic
Language(s)
en
Contributor(s)
Endimiani, Andreaorcid-logo
Institut für Infektionskrankheiten
Guilarte, Yuvia
Institut für Infektionskrankheiten
Tinguely, Regula
Institut für Infektionskrankheiten, Allgemeine Bakteriologie
Hirzberger, Lea
Institut für Infektionskrankheiten
Selvini, Sylvia
Institut für Infektionskrankheiten, Allgemeine Bakteriologie
Lupo, Agnese
Institut für Infektionskrankheiten
Hauser, Christoph Victororcid-logo
Universitätsklinik für Infektiologie
Furrer, Hansjakoborcid-logo
Universitätsklinik für Infektiologie
Additional Credits
Institut für Infektionskrankheiten
Institut für Infektionskrankheiten, Allgemeine Bakteriologie
Universitätsklinik für Infektiologie
Series
BMC infectious diseases
Publisher
BioMed Central
ISSN
1471-2334
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: ae9592 [15.12. 16:43]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo